Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Jiwei Zhang1, Fen Ma1, Zhe Li2

  • 1Shanghai Key Laboratory of Compound Chinese Medicines The MOE Key Laboratory for Standardization of Chinese Medicines Institute of Chinese Materia Medica Shanghai University of Traditional Chinese Medicine Shanghai China.

Medcomm
|April 25, 2024
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma.

Journal for immunotherapy of cancer·2026
Same author

A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity.

Nature biomedical engineering·2025
Same author

Notoginsenoside Ft1 inhibits colorectal cancer growth by increasing CD8<sup>+</sup> T cell proportion in tumor-bearing mice through the USP9X signaling pathway.

Chinese journal of natural medicines·2024
Same author

Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma.

Communications biology·2024
Same author

Structural insights into gating mechanism and allosteric regulation of NMDA receptors.

Current opinion in neurobiology·2023
Same author

Cancer and Atrial Fibrillation Comorbidities Among 25 Million Citizens in Shanghai, China: Medical Insurance Database Study.

JMIR public health and surveillance·2023

Nuclear factor kappa B subunit 2 (NFKB2) promotes colorectal cancer (CRC) growth and immune escape by upregulating PD-L1. Targeting NFKB2 may enhance immunotherapy effectiveness for CRC patients.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Context:

  • Colorectal cancer (CRC) exhibits complex immune evasion mechanisms.
  • Nuclear factor kappa B subunit 2 (NFKB2) is implicated in cancer progression.

Purpose:

  • To elucidate the molecular mechanism and function of NFKB2 in CRC.
  • To evaluate NFKB2 as a potential therapeutic target for CRC.

Summary:

  • NFKB2 is upregulated in advanced CRC with hepatic metastasis, promoting tumor growth via CD8+ T-cell exhaustion.
  • NFKB2 interacts with STAT2, increasing STAT2 phosphorylation and PD-L1 expression.
  • Inhibition of NFKB2 with Rg5 reduced PD-L1 and improved response to PD-1 blockade immunotherapy.

Impact:

Related Experiment Videos

  • Identifies the NFKB2-STAT2/PD-L1 axis as a key regulator of CRC immune suppression.
  • Suggests targeting NFKB2 can enhance CRC immunotherapy efficacy.
  • Provides novel insights into CRC immune escape mechanisms.